Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Waverley Pharma Inc.

Market Cap 810K 578K 502K 463K 434K 55.38M 827K 5.52M 2.14M 26.7M 2.17M 2.12M 92.82M P/E Ratio 2024
-0.57x
P/E Ratio 2025 -2.16x
Enterprise Value 4.21M 3.01M 2.61M 2.4M 2.25M 288M 4.3M 28.68M 11.1M 139M 11.28M 11.04M 482M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 day+50.00%
1 week+50.00%
Current month+50.00%
1 month+50.00%
3 months-40.00%
Current year-25.00%
1 week 0.02
Extreme 0.015
0.02
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.14
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 01/02/2020
Director of Finance/CFO - 01/01/2020
Director TitleAgeSince
Chairman 79 14/12/2016
Director/Board Member 54 14/12/2016
Director/Board Member 47 20/06/2024
Date Insider Type Main position Quantity % Market Cap.
24/06/24Other

Director

0 0%
18/08/21Other

Chairman

0 0%
18/08/21Option

Chairman

10,000,000 18.5185%
Change 5-day change 1-year change 3-year change Capi.($)
+50.00%+50.00%0.00%-57.14% 578K
+0.90%+2.27%+54.88%+111.73% 55.58B
+0.03%+0.33%+49.22%+43.94% 43.47B
+3.93%-0.06%-15.10%-18.04% 22.64B
+5.27%-7.82%-1.29%+388.48% 20.96B
+3.81%-5.07%+12.00%-29.52% 15.79B
+0.53%+0.81%+9.43%-39.85% 15.3B
+1.75%+1.92%+29.13%+178.65% 13.45B
+5.27%+5.54%+14.25% - 11.74B
-5.27%-0.43%+87.77%+208.02% 10.96B
Average +6.63%-0.38%+24.03%+87.36% 20.99B
Weighted average by Cap. +1.68%+0.76%+31.81%+98.22%

Financials

2024 2025
Net sales 475K 339K 295K 272K 254K 32.5M 485K 3.24M 1.25M 15.67M 1.27M 1.25M 54.48M 1.35M 964K 836K 771K 722K 92.28M 1.38M 9.2M 3.56M 44.48M 3.62M 3.54M 155M
Net income -947K -676K -587K -541K -507K -64.75M -967K -6.45M -2.5M -31.21M -2.54M -2.48M -109M -499K -356K -309K -285K -267K -34.13M -510K -3.4M -1.32M -16.45M -1.34M -1.31M -57.21M
Net Debt 2.83M 2.02M 1.75M 1.62M 1.51M 194M 2.89M 19.29M 7.47M 93.29M 7.59M 7.42M 324M 3.4M 2.43M 2.11M 1.94M 1.82M 232M 3.47M 23.16M 8.97M 112M 9.11M 8.92M 390M
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. WAVE Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!